Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Canon has conducted 18 buybacks in the last 15 years. Every single one has been the same size. And the parameter-setting and how they are executed is... particular.</li>
<li>For those with Canon to execute, using the information about patterns may be helpful. </li>
<li>For those interested in a trade, there may be one here.</li>
</ul>


Canon has conducted 18 buybacks in the last 15 years. Every single one has been the same size. And the parameter-setting and how they are executed is... particular.
For those with Canon to execute, using the information about patterns may be helpful. 
For those interested in a trade, there may be one here.


Canon Buyback - 18th in a Row at the Same Size, But This Time With a Running Head Start

Equity Analyst, LightStream Research

Shifara Samsudeen, FCMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/fujifilm-holdings-corp" target="_blank" data-smartkarma-citation="entities:16353:1" rel="noopener"></a>Fujifilm delivered its 4Q and full-year FY03/2023 results today. Revenue and OP increased 15.0% and 63.2% YoY to ¥764.7bn (vs consensus ¥715.7bn) and ¥70.4bn (vs consensus ¥62.5bn) respectively.</li>
<li>The company’s full-year revenue and OP were above its own guidance as well as consensus, and we think <a href="https://www.smartkarma.com/entities/fujifilm-holdings-corp" target="_blank" data-smartkarma-citation="entities:16353:1" rel="noopener">FUJIFILM Holdings (4901 JP)</a> ’s guidance for FY03/2024E is too conservative.</li>
<li>The market continues to value Fujifilm as an imaging company and not in line with healthcare peers suggesting there is significant upside to the current valuation multiples.</li>
</ul>



Fujifilm delivered its 4Q and full-year FY03/2023 results today. Revenue and OP increased 15.0% and 63.2% YoY to ¥764.7bn (vs consensus ¥715.7bn) and ¥70.4bn (vs consensus ¥62.5bn) respectively.
The company’s full-year revenue and OP were above its own guidance as well as consensus, and we think FUJIFILM Holdings (4901 JP) ’s guidance for FY03/2024E is too conservative.
The market continues to value Fujifilm as an imaging company and not in line with healthcare peers suggesting there is significant upside to the current valuation multiples.


Fujifilm FQ4: Strong Earnings Beat and There's Further Upside

<ul>
<li>
<a href="https://www.smartkarma.com/entities/fujifilm-holdings-corp" target="_blank" data-smartkarma-citation="entities:16353:1" rel="noopener">FUJIFILM Holdings (4901 JP)</a> delivered 3QFY03/2023 results today. Revenue and OP increased 13.5% and 4.1% YoY respectively to JPY744.4bn (consensus JPY717.1bn) and JPY81.8bn (consensus JPY80.0bn).</li>
<li>Covid-19 related projects running its course had a slight impact on  healthcare segment but we would not be too worried as new product launches and markets will offset that decline.</li>
<li>Market continues to value Fujifilm as an image company and not a healthcare stock and there is more than 30% upside to the current share price.</li>
</ul>



FUJIFILM Holdings (4901 JP) delivered 3QFY03/2023 results today. Revenue and OP increased 13.5% and 4.1% YoY respectively to JPY744.4bn (consensus JPY717.1bn) and JPY81.8bn (consensus JPY80.0bn).
Covid-19 related projects running its course had a slight impact on  healthcare segment but we would not be too worried as new product launches and markets will offset that decline.
Market continues to value Fujifilm as an image company and not a healthcare stock and there is more than 30% upside to the current share price.


Fujifilm: Robust Quarter; Recent M&A to Drive Healthcare and Materials Biz Further

<ul>
<li>
<a href="https://www.smartkarma.com/entities/canon-inc" target="_blank" data-smartkarma-citation="entities:1:1" rel="noopener">Canon Inc (7751 JP)</a> has just started its 17th buyback in 15 years. Like the 16 before, this one is for ¥50bn. </li>
<li>The patterns/dynamics of the canon buybacks in the past are remarkable when compared to buybacks of other companies. </li>
<li>There are outperformance and under-performance patterns vs Peers, and it is worth taking note if you have a position to trade. </li>
</ul>



Canon Inc (7751 JP) has just started its 17th buyback in 15 years. Like the 16 before, this one is for ¥50bn. 
The patterns/dynamics of the canon buybacks in the past are remarkable when compared to buybacks of other companies. 
There are outperformance and under-performance patterns vs Peers, and it is worth taking note if you have a position to trade. 


Looking at Canon Buyback Dynamics History - Patterns Vs Peers Gives Execution Hints

<ul>
<li>
<a href="https://www.smartkarma.com/entities/canon-inc" target="_blank" data-smartkarma-citation="entities:1:1" rel="noopener">Canon Inc (7751 JP)</a> reported Q2 earnings early last week. Shares dropped 4% the next day but closed down only 1%. Now they are above the prior close. </li>
<li>They biked the dividend nicely (was ¥45/share last year, guided to ¥50 this year, but made ¥60/share instead. </li>
<li>And now they have announced another ¥50bn buyback on top of the one announced in May. Fourth time in 14 years a second tranche is announced in one year. </li>
</ul>



Canon Inc (7751 JP) reported Q2 earnings early last week. Shares dropped 4% the next day but closed down only 1%. Now they are above the prior close. 
They biked the dividend nicely (was ¥45/share last year, guided to ¥50 this year, but made ¥60/share instead. 
And now they have announced another ¥50bn buyback on top of the one announced in May. Fourth time in 14 years a second tranche is announced in one year. 


Canon (7751) - Second Buyback This Year - Last Happened in 2014

Japan

Konica Minolta Inc is mainly engaged in manufacturing office equipment and performance materials. It also operates health care businesses. The Company also makes copiers, personal computer peripherals, optical lenses, and measuring instruments.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Konica Minolta (4902 JP)

Canon Buyback - 18th in a Row at the Same Size, But This Time With a Running Head Start

Canon (7751) reported salutary Q1 earnings, and revised up FY forecasts. The stock responded well vs Peers. Peers have since reported, but it...

Travis Lundy

Fujifilm FQ4: Strong Earnings Beat and There's Further Upside

Fujifilm's FQ4 earnings beat consensus by a huge margin. Market continues to value Fujifilm as an imaging services stock and not as a healthcare...

Shifara Samsudeen, FCMA, CGMA

Fujifilm: Robust Quarter; Recent M&A to Drive Healthcare and Materials Biz Further

Covid-19 related projects running its course has had a slight impact on the healthcare segment but we would not be too worried. Recent M&A in...

Shifara Samsudeen, FCMA, CGMA

Looking at Canon Buyback Dynamics History - Patterns Vs Peers Gives Execution Hints

Canon has done 6 buybacks in the last 15 years. They all have particular terms and patterns in common and that can help guide execution.

Travis Lundy

Canon (7751) - Second Buyback This Year - Last Happened in 2014

Canon last week announced OK Q2 earnings, and higher FY22 guidance, raising it for the second quarter in a row. It also hiked its div guidance. Now...

Travis Lundy

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)